Chemiluminescence Immunoassay Market

7500+ companies worldwide approach us every year for their revenue growth initiatives
Global top 2000 strategist rely on us for their growth strategies.
80% of fortune 2000 companies rely on our research to identify new revenue sources.
30000 High Growth Opportunities
95% renewal rate
KNOW MORE
  1. HOME
  2. Top Market Reports
  3. Chemiluminescence Immunoassay Market

Chemiluminescence Immunoassay Market by Product (Instrument, Consumable), Technology (Chemiluminescence Enzyme, Microparticle Chemiluminescence), Sample (Blood, Urine), Application (Infectious Disease, Oncology), End User - Global Forecast to 2028

FREE BROCHURE FREE SAMPLE REPORT
Report Code: MD 8709 Jul, 2023, by marketsandmarkets.com

Updated on : Aug 22, 2024

The global chemiluminescence immunoassay market in terms of revenue was estimated to be worth $13.2 billion in 2023 and is poised to reach $19.0 billion by 2028, growing at a CAGR of 7.5% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Market growth is largely driven by the increasing prevalence of infectious diseases and cancer and the growing geriatric population in chemiluminescence immunoassay.

On the other hand, the unfavorable reimbursement scenario and lack of skilled professionals may restrain the growth of this market to a certain extent.

Attractive Opportunities in the Chemiluminescence Immunoassay Market

Chemiluminescence Immunoassay Market

To know about the assumptions considered for the study, Request for Free Sample Report

Chemiluminescence Immunoassay Market

Chemiluminescence Immunoassay Market Dynamics

DRIVER: Rising incidence of chronic and infectious diseases across the globe

During recent years, there has been a significant rise in the occurrence of infectious as well as diseases. With rising prevalence the rate of their diagnosis has increased significantly across the globe. The WHO underlined the global concern of HIV, which claimed over 38.4 million in 2021. Due to the efforts of international organizations and the WHO, the disease has been managed with antiviral therapies. Diagnosis has substantially helped disease management. Besides, according to the IDF Diabetes Atlas, globally, about 537 million adults (20–79 years) are living with diabetes—1 in 10. This number is predicted to rise to 643 million by 2030 and 783 million by 2045. Over 3 in 4 adults with diabetes live in low- and middle-income countries. Diabetes is responsible for 6.7 million deaths in 2021—1 every 5 seconds. The increased prevalence of infectious and chronic diseases is hence a driving factor for the growth of the CLIA market.

OPPORTUNITY: Increasing number of collaborations and partnerships in the CLIA market

Collaboration and partnership are essential in the field of CLIA to drive innovation, expand applications, and advance the development and adoption of new technologies. Here are some key aspects of collaboration and partnership in the context of CLIA. Some of the recent developments include in February 2022, Sysmex established a business tie-up with KAINOS Laboratories to strengthen the former company’s offering of immunochemistry diagnostic reagents and develop diagnostic reagents for HISCL systems. These developments help in the growth of both the players involved, which eventually helps in the growth of the market.

RESTRAINT: High cost of CLIA related products

The high cost of CLIA systems and reagents can be a significant challenge to its widespread adoption and implementation. CLIA requires specialized equipment and instrumentation, including chemiluminescence analyzers, luminometers, and other laboratory devices. These instruments are often high-end and technologically advanced, which come with significantly higher costs for their purchase, maintenance, and calibration. Also, CLIA utilizes specific reagents and consumables, such as antibodies, detection agents, substrates, and assay plates. These systems may be sometimes unaffordable to small scale laboratories, or academic or research organizations which can hamper the adoption of CLIA systems, hence impacting growth of the market.

CHALLENGE: Lack of skilled professionals and aging workforce

The dearth of a skilled workforce has been a challenge for several decades, resulting in an aging workforce and declining enrolment in training programs. It takes almost five to ten years of continuous practice in clinical laboratory work for technicians to gain expertise.

Europe reportedly has low numbers of clinical technicians. The Gatsby Foundation stated in 2019 that over 1.5 million people serve in the health, engineering, science, and technology domains. Over 50,000 retire every year, and 700,000 technicians will be required to meet the soaring demands in the next decade. The Duquesne University School of Nursing has stated that by 2025, there will be a shortage of over 29,400 nurse practitioners and more than 400,000 home health aides.

Chemiluminescence Immunoassay Ecosystem/Market Map

Chemiluminescence Immunoassay Market Ecosystem

Consumables segment accounted for the largest share of the chemiluminescence immunoassay industry in 2022, by product

Based on product, the chemiluminescence immunoassay market is segmented as instruments and consumables. The consumables segment accounted for a significant share in the market in 2022. The recurring expenses associated with the frequent purchase of reagents & kits is a significant factor contributing to the market's growth. Besides, the availability of advanced consumables that offer better performance and reliability attributes to their widespread adoption resulting to the segment's growth.

Lab tests segment accounted for the largest share in the chemiluminescence immunoassay industry in 2022, by test type

On the basis of technology, the global chemiluminescence immunoassay market is categorized into Chemiluminescence Enzyme Technology (CLEIA), Electrochemiluminescence immunoassay (ECLI), and Microparticle Chemiluminescence Immunoassay. In 2022, the CLEIA segment held the largest share in the market, by technology. The growth of the segment can be attributed to its high sensitivity and a broad dynamic range of applications ranging from clinical diagnostics, pharmaceutical research, environmental analysis, and food safety testing, among others.

Blood sample segment accounted for the largest share in the chemiluminescence immunoassay industry in 2022, by sample type

Based on sample type, the chemiluminescence immunoassay market has been segmented into blood, saliva, urine, and other sample types. In 2022, the blood segment accounted for the largest share of the market. Blood enables the diagnosis of various indications that are not easily diagnosed using urine or saliva sample. Besides, with the rise in the number of blood donations and initiatives in support of blood screening, the segment is anticipated to also grow at the highest rate during the forecast period.

North America accounted for the largest share of the chemiluminescence immunoassay industry in 2022

The chemiluminescence immunoassay market is segmented into four major regions: North America, Europe, the Asia Pacific, and the Rest of the World. In 2022, North America emerged as the leading contributor, claiming the largest portion of the market share in the chemiluminescence immunoassay industry. With the presence of major players in the region, North America has witnessed various technological advancements in the field of chemiluminescence immunoassay. These companies have significant expertise, resources, and established sales networks, which contribute to the region’s market dominance. Examples of prominent chemiluminescence immunoassay companies in North America include Danaher Corporation (US) and Abbott Laboratories (US).

Chemiluminescence Immunoassay Market by Region

To know about the assumptions considered for the study, download the pdf brochure

The major players in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation. (US), Siemens Healthineers AG (Germany), Abbott Laboratories (US), and DiaSorin S.p.A. (Italy). The market leadership of these players is owing to their comprehensive product portfolios and expansive global footprint. These dominant market players have several advantages, including strong research and development budgets,strong marketing and distribution networks, and well-established brand recognition.

Scope of the Chemiluminescence Immunoassay Industry

Report Metric 

Details 

Market Revenue in 2023

$13.2 billion

Projected Revenue by 2028

$19.0 billion

Revenue Rate

Poised to Grow at a CAGR of 7.5%

Market Driver

Rising incidence of chronic and infectious diseases across the globe

Market Opportunity

Increasing number of collaborations and partnerships in the CLIA market

This research report categorizes the Chemiluminescence Immunoassay Market to forecast revenue and analyze trends in each of the following submarkets:

By Region

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

By Product

  • Consumables
  • Instruments

By Technology

  • Chemiluminescence Enzyme Technology (CLEIA)
  • Electrochemiluminescence immunoassay (ECLI)
  • Microparticle Chemiluminescence Immunoassay

By Sample Type

  • Blood
  • Urine
  • Saliva
  • Other Sample Types

By Application

  • Infectious Disease
  • Endocrinology
  • Oncology
  • Cardiology
  • Allergy Diagnostics
  • Autoimmune Disorders
  • Blood Screening
  • Bone & Mineral Disorders
  • Toxicology
  • Newborn Screening
  • Therapeutic Drug Monitoring
  • Metabolic Disorder
  • Gastroenterology
  • Neurology
  • Respiratory
  • Other Applications

By End User

  • Hospitals
  • Clinical Laboratories
  • Pharmaceuticals & Biotechnology Companies and Contract Research Organizations
  • Other End Users

Recent Developments of Chemiluminescence Immunoassay Industry

  • In May 2023, EUROIMMUN’s parent company PerkinElmer’s life science and diagnostics business segment, has been rebranded as Revvity.
  • In December 2022, Mindray launched CLIA-based assays, IL-6, PCT, and sCD14-S, which have high sensitivity, a wide linearity range, great precision, and good anti-interference ability.
  • In December 2022, Sysmex received manufacturing and marketing approval in Japan for the HISCL β-Amyloid 1-42 Assay Kit and the HISCL β-Amyloid 1-40 Assay Kit to measure amyloid beta (Aβ) in the blood.
  • In November 2022 Getein Biotech, Inc. launched MAGICL 6000, a compact and innovative chemiluminescence immunoassay analyzer used in mid to high-workflow laboratories
  • In June 2022, QuidelOrtho Corporation was formed through a transaction between Quidel Corporation and Ortho Clinical Diagnostics to form a leading in vitro diagnostics company.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 31)
    1.1 STUDY OBJECTIVES 
    1.2 CHEMILUMINESCENCE IMMUNOASSAY INDUSTRY DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 MARKET SCOPE 
           1.3.1 MARKETS COVERED
                    FIGURE 1 CHEMILUMINESCENCE IMMUNOASSAY MARKET SEGMENTATION
           1.3.2 GEOGRAPHICAL SCOPE
           1.3.3 YEARS CONSIDERED
    1.4 CURRENCY CONSIDERED 
    1.5 STAKEHOLDERS 
 
2 RESEARCH METHODOLOGY (Page No. - 36)
    2.1 RESEARCH APPROACH 
          FIGURE 2 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY DATA
                    2.1.2.1 Primary sources
                    2.1.2.2 Key data from primary sources
                    2.1.2.3 Key industry insights
                                FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY AND DEMAND SIDE PARTICIPANTS
                                FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
    2.2 MARKET SIZE ESTIMATION 
          FIGURE 5 REVENUE SHARE ANALYSIS ILLUSTRATION
          FIGURE 6 MARKET ESTIMATION FROM IVD MARKET
          FIGURE 7 MARKET ESTIMATION FROM IMMUNOASSAY MARKET
          FIGURE 8 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS OF MARKET
          FIGURE 9 TOP-DOWN APPROACH
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 10 DATA TRIANGULATION METHODOLOGY
    2.4 MARKET SHARE ANALYSIS 
    2.5 STUDY ASSUMPTIONS 
    2.6 RESEARCH LIMITATIONS 
    2.7 RISK ASSESSMENT 
          TABLE 1 RISK ASSESSMENT: MARKET
    2.8 GROWTH RATE ASSUMPTIONS 
    2.9 IMPACT OF RECESSION ON MARKET 
 
3 EXECUTIVE SUMMARY (Page No. - 51)
    FIGURE 11 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2023 VS. 2028 (USD BILLION)
    FIGURE 12 CHEMILUMINESCENCE IMMUNOASSAY INDUSTRY, BY TECHNOLOGY, 2023 VS. 2028 (USD BILLION)
    FIGURE 13 MARKET, BY SAMPLE TYPE, 2023 VS. 2028 (USD BILLION)
    FIGURE 14 MARKET, BY APPLICATION, 2023 VS. 2028 (USD BILLION)
    FIGURE 15 MARKET, BY END USER, 2023 VS. 2028 (USD BILLION)
    FIGURE 16 GEOGRAPHICAL SNAPSHOT OF MARKET
 
4 PREMIUM INSIGHTS (Page No. - 57)
    4.1 CHEMILUMINESCENCE IMMUNOASSAY MARKET OVERVIEW 
          FIGURE 17 INCREASING INCIDENCE OF DISEASES AND TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET
    4.2 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY INDUSTRY, BY PRODUCT (2022) 
          FIGURE 18 CONSUMABLES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
    4.3 GEOGRAPHICAL GROWTH OPPORTUNITIES IN MARKET 
          FIGURE 19 CHINA AND INDIA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
    4.4 MARKET: REGIONAL MIX 
          FIGURE 20 ASIA PACIFIC TO WITNESS HIGHEST GROWTH RATE DURING STUDY PERIOD
    4.5 MARKET: DEVELOPED VS. DEVELOPING MARKETS 
          FIGURE 21 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING STUDY PERIOD
 
5 MARKET OVERVIEW (Page No. - 62)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 22 CHEMILUMINESCENCE IMMUNOASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Increasing incidences of chronic and infectious diseases globally
                                FIGURE 23 INCREASING INCIDENCES OF DIABETES (GLOBAL)
                                FIGURE 24 NUMBER OF PEOPLE WITH CHRONIC CONDITIONS IN US, 1995–2030 (MILLION INDIVIDUALS)
                    5.2.1.2 Advancements in improving chemiluminescence immunoassay technologies in recent years
                    5.2.1.3 Growth of biotechnology and biopharmaceutical industries
                    5.2.1.4 Rapid increase in geriatric population globally
                                FIGURE 25 GLOBAL GERIATRIC POPULATION, BY REGION, 2019 VS. 2050 (MILLION)
                    5.2.1.5 Shift toward personalized medicines and individualized treatment decisions
           5.2.2 RESTRAINTS
                    5.2.2.1 High cost of chemiluminescence systems and reagents
                    5.2.2.2 Lack of regular quality control procedures for monitoring and detecting cross-reactivity and interference
           5.2.3 OPPORTUNITIES
                    5.2.3.1 High growth prospects for players in emerging economies
                    5.2.3.2 Increasing number of collaborations and partnerships
           5.2.4 CHALLENGES
                    5.2.4.1 Unfavorable reimbursement scenario and budgetary constraints in healthcare systems
                    5.2.4.2 Lack of skilled professionals and aging workforce
    5.3 VALUE CHAIN ANALYSIS 
          FIGURE 26 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
    5.4 SUPPLY CHAIN ANALYSIS 
          FIGURE 27 DIRECT DISTRIBUTION TO BE PREFERRED STRATEGY FOR PROMINENT COMPANIES
    5.5 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 2 HIGH CONSOLIDATION IN MARKET TO RESTRICT ENTRY OF NEW PLAYERS
           5.5.1 DEGREE OF COMPETITION
           5.5.2 BARGAINING POWER OF SUPPLIERS
           5.5.3 BARGAINING POWER OF BUYERS
           5.5.4 THREAT OF SUBSTITUTES
           5.5.5 THREAT OF NEW ENTRANTS
    5.6 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.6.1 KEY STAKEHOLDERS IN BUYING PROCESS
                    FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
                    TABLE 3 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
           5.6.2 BUYING CRITERIA
                    FIGURE 29 KEY BUYING CRITERIA FOR MAJOR END USERS
                    TABLE 4 KEY BUYING CRITERIA, BY END USER
    5.7 REGULATORY LANDSCAPE 
           5.7.1 US
                    TABLE 5 US: CLASSIFICATION OF IMMUNOASSAY PRODUCTS
                    FIGURE 30 US: REGULATORY PROCESS FOR IVD DEVICES
           5.7.2 CANADA
                    FIGURE 31 CANADA: REGULATORY PROCESS FOR IVD DEVICES
           5.7.3 EUROPE
                    TABLE 6 EUROPE: CLASSIFICATION OF IVD DEVICES
           5.7.4 JAPAN
                    FIGURE 32 JAPAN: REGULATORY PROCESS FOR IVD DEVICES
                    TABLE 7 JAPAN: CLASSIFICATION OF IVD REAGENTS
                    TABLE 8 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
           5.7.5 CHINA
                    TABLE 9 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
           5.7.6 INDIA
                    FIGURE 33 INDIA: REGULATORY PROCESS FOR IVD DEVICES
           5.7.7 INDONESIA
                    TABLE 10 INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES
           5.7.8 RUSSIA
                    TABLE 11 RUSSIA: CLASSIFICATION OF IVD DEVICES
           5.7.9 SAUDI ARABIA
                    TABLE 12 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
           5.7.10 MEXICO
                     FIGURE 34 MEXICO: REGULATORY PROCESS FOR IVD DEVICES
                     TABLE 13 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
           5.7.11 BRAZIL
                     FIGURE 35 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES
           5.7.12 SOUTH KOREA
                     TABLE 14 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
           5.7.13 MIDDLE EAST
           5.7.14 AFRICA
    5.8 TECHNOLOGY ANALYSIS 
          TABLE 15 RECENT PRODUCT LAUNCHES WITH ADVANCED TECHNOLOGIES IN CHEMILUMINESCENCE IMMUNOASSAY INDUSTRY
    5.9 TRADE ANALYSIS 
           5.9.1 TRADE ANALYSIS FOR CHEMILUMINESCENCE IMMUNOASSAYS
                    TABLE 16 IMPORT DATA FOR HS CODE 902780, BY COUNTRY, 2018–2022 (USD MILLION)
                    TABLE 17 EXPORT DATA FOR HS CODE 902780, BY COUNTRY, 2018–2022 (USD MILLION)
    5.10 ECOSYSTEM MAPPING 
           FIGURE 36 ECOSYSTEM MAPPING OF MARKET
           5.10.1 ROLE IN ECOSYSTEM
           5.10.2 KEY PLAYERS OPERATING IN MARKET
    5.11 PATENT ANALYSIS 
    5.12 KEY CONFERENCES AND EVENTS IN 2023–2024 
           TABLE 18 LIST OF CONFERENCES AND EVENTS IN 2023–2024
    5.13 PRICING ANALYSIS 
           5.13.1 AVERAGE SELLING PRICE, BY APPLICATION (KEY PLAYERS)
                     TABLE 19 PRICE RANGE OFFERED BY KEY PLAYERS, BY APPLICATION (USD)
    5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
 
6 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT (Page No. - 92)
    6.1 INTRODUCTION 
          TABLE 20 CHEMILUMINESCENCE IMMUNOASSAY INDUSTRY, BY PRODUCT, 2021–2028 (USD MILLION)
    6.2 CONSUMABLES 
           6.2.1 CONSUMABLES TO ACCOUNT FOR LARGEST SHARE OF MARKET DURING STUDY PERIOD
                    TABLE 21 LIST OF CHEMILUMINESCENCE IMMUNOASSAY CONSUMABLES AVAILABLE
                    TABLE 22 MARKET FOR CONSUMABLES, BY REGION, 2021–2028 (USD MILLION)
    6.3 INSTRUMENTS 
           6.3.1 INCREASING ADVANCES WITH HIGH-THROUGHPUT CAPACITIES AND GROWING AUTOMATION TRENDS TO DRIVE MARKET
                    TABLE 23 LIST OF CHEMILUMINESCENCE IMMUNOASSAY INSTRUMENTS AVAILABLE
                    TABLE 24 MARKET FOR INSTRUMENTS, BY REGION, 2021–2028 (USD MILLION)
 
7 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY (Page No. - 98)
    7.1 INTRODUCTION 
          TABLE 25 MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
    7.2 CHEMILUMINESCENCE ENZYME 
           7.2.1 HIGH RELIABILITY OF BLOOD TESTS IN CLINICAL DIAGNOSTICS AND PHARMACEUTICAL RESEARCH TO DRIVE MARKET
                    TABLE 26 MARKET FOR CHEMILUMINESCENCE ENZYME, BY REGION, 2021–2028 (USD MILLION)
    7.3 ELECTROCHEMILUMINESCENCE IMMUNOASSAY 
           7.3.1 INCREASED GENERATION OF EXCITED STATES THROUGH BETTER ELECTRODE VARIATION TO DRIVE MARKET
                    TABLE 27 MARKET FOR ELECTROCHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2021–2028 (USD MILLION)
    7.4 MICROPARTICLE CHEMILUMINESCENCE IMMUNOASSAY 
           7.4.1 HIGHER COSTS AND GREATER CHANCES OF CROSS-REACTIVITY DUE TO MULTIPLEXING TO LIMIT MARKET
                    TABLE 28 MARKET FOR MICROPARTICLE CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2021–2028 (USD MILLION)
 
8 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE (Page No. - 103)
    8.1 INTRODUCTION 
          TABLE 29 MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
    8.2 BLOOD 
           8.2.1 HIGH RELIABILITY OF BLOOD TESTS FOR IMMUNOASSAY DIAGNOSTIC PROCEDURES AND HEALTH SCREENING TO DRIVE MARKET
                    TABLE 30 MARKET FOR BLOOD, BY REGION, 2021–2028 (USD MILLION)
    8.3 URINE 
           8.3.1 INCREASING USE IN LAW ENFORCEMENT AND DRUG TESTING CENTERS TO DRIVE MARKET
                    TABLE 31 MARKET FOR URINE, BY REGION, 2021–2028 (USD MILLION)
    8.4 SALIVA 
           8.4.1 CONVENIENCE AND EASY TESTING OF BIOLOGICALLY ACTIVE PARTS OF HORMONES TO DRIVE MARKET
                    TABLE 32 MARKET FOR SALIVA, BY REGION, 2021–2028 (USD MILLION)
    8.5 OTHER SAMPLE TYPES 
                    TABLE 33 MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2021–2028 (USD MILLION)
 
9 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION (Page No. - 109)
    9.1 INTRODUCTION 
          TABLE 34 MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
    9.2 INFECTIOUS DISEASES 
           9.2.1 RISING PREVALENCE OF INFECTIOUS DISEASES GLOBALLY AMONG ALL AGE GROUPS TO DRIVE MARKET
                    TABLE 35 MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION)
    9.3 ENDOCRINOLOGY 
           9.3.1 RISING INCIDENCES OF DIABETES GLOBALLY TO DRIVE MARKET
                    TABLE 36 MARKET FOR ENDOCRINOLOGY, BY REGION, 2021–2028 (USD MILLION)
    9.4 ONCOLOGY 
           9.4.1 RISING BURDEN OF CANCER AND EMPHASIS ON EARLY DISEASE DIAGNOSIS TO DRIVE MARKET
                    TABLE 37 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
                    TABLE 38 MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION)
    9.5 CARDIOLOGY 
           9.5.1 HIGH BURDEN OF CARDIOVASCULAR DISEASES AMONG ALL AGE GROUPS TO DRIVE MARKET
                    TABLE 39 MARKET FOR CARDIOLOGY, BY REGION, 2021–2028 (USD MILLION)
    9.6 ALLERGY DIAGNOSTICS 
           9.6.1 GROWING PREVALENCE OF ALLERGIES TO REGISTER INCREASED DEMAND FOR CHEMILUMINESCENCE IMMUNOASSAYS
                    TABLE 40 MARKET FOR ALLERGY DIAGNOSTICS, BY REGION, 2021–2028 (USD MILLION)
    9.7 BLOOD SCREENING 
           9.7.1 RISING VOLUME OF BLOOD DONATIONS AND INCREASING INCIDENCES OF BLOOD-RELATED DISORDERS TO DRIVE MARKET
                    TABLE 41 MARKET FOR BLOOD SCREENING, BY REGION, 2021–2028 (USD MILLION)
    9.8 AUTOIMMUNE DISORDERS 
           9.8.1 GROWING PREVALENCE OF AUTOIMMUNE DISORDERS AND RISING ECONOMIC BURDEN OF DISEASE MANAGEMENT TO DRIVE MARKET
                    TABLE 42 MARKET FOR AUTOIMMUNE DISORDERS, BY REGION, 2021–2028 (USD MILLION)
    9.9 BONE & MINERAL DISORDERS 
           9.9.1 HIGH DISORDER PREVALENCE TO INDICATE STRONG GROWTH OPPORTUNITIES FOR IMMUNOASSAYS
                    TABLE 43 MARKET FOR BONE & MINERAL DISORDERS, BY REGION, 2021–2028 (USD MILLION)
    9.1 TOXICOLOGY 
           9.10.1 INCREASED DRUG-OF-ABUSE TESTING AND HIGHER ILLICIT DRUG CONSUMPTION TO DRIVE MARKET
                    TABLE 44 MARKET FOR TOXICOLOGY, BY REGION, 2021–2028 (USD MILLION)
    9.11 NEWBORN SCREENING 
           9.11.1 CHEMILUMINESCENCE IMMUNOASSAYS TO BE ROUTINELY USED AS FIRST-TIER NEWBORN SCREENING PROTOCOL
                    TABLE 45 MARKET FOR NEWBORN SCREENING, BY REGION, 2021–2028 (USD MILLION)
    9.12 THERAPEUTIC DRUG MONITORING 
           9.12.1 RAPID DETECTION TIME AND GOOD SPECIFICITY TO DRIVE MARKET
                    TABLE 46 MARKET FOR THERAPEUTIC DRUG MONITORING, BY REGION, 2021–2028 (USD MILLION)
    9.13 METABOLIC DISORDERS 
           9.13.1 RISING PREVALENCE OF METABOLIC DISORDERS TO DRIVE MARKET
                    FIGURE 37 GLOBAL INCIDENCE OF DIABETES
                    TABLE 47 MARKET FOR METABOLIC DISORDERS, BY REGION, 2021–2028 (USD MILLION)
    9.14 GASTROENTEROLOGY 
           9.14.1 INCREASING INCIDENCE OF GASTROINTESTINAL TRACT INFECTIONS AND SERIOUS GASTRIC DISEASES TO DRIVE MARKET
                    TABLE 48 MARKET FOR GASTROENTEROLOGY, BY REGION, 2021–2028 (USD MILLION)
    9.15 NEUROLOGY 
           9.15.1 EFFECTIVE DETECTION, MONITORING, AND MANAGEMENT OF NEUROLOGICAL DISORDERS TO DRIVE SEGMENT
                    TABLE 49 MARKET FOR NEUROLOGY, BY REGION, 2021–2028 (USD MILLION)
    9.16 RESPIRATORY 
           9.16.1 EASY DETECTION AND DIAGNOSIS OF RESPIRATORY DISEASES TO DRIVE MARKET
                    TABLE 50 MARKET FOR RESPIRATORY, BY REGION, 2021–2028 (USD MILLION)
    9.17 OTHER APPLICATIONS 
                    TABLE 51 MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
 
10 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER (Page No. - 129)
     10.1 INTRODUCTION 
             TABLE 52 CHEMILUMINESCENCE IMMUNOASSAY INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
     10.2 HOSPITALS 
             10.2.1 GROWING PATIENT POPULATION AND TESTING VOLUMES TO DRIVE MARKET
                        TABLE 53 MARKET FOR HOSPITALS, BY REGION, 2021–2028 (USD MILLION)
     10.3 CLINICAL LABORATORIES 
             10.3.1 RISING CLINICAL TEST VOLUMES AND REQUIREMENTS TO DRIVE SEGMENT
                        TABLE 54 MARKET FOR CLINICAL LABORATORIES, BY REGION, 2021–2028 (USD MILLION)
     10.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS 
             10.4.1 RISING DRUG DISCOVERIES AND CLINICAL STUDIES TO DRIVE MARKET
                        TABLE 55 MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION)
     10.5 OTHER END USERS 
             TABLE 56 MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION)
 
11 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY REGION (Page No. - 137)
     11.1 INTRODUCTION 
             TABLE 57 CHEMILUMINESCENCE IMMUNOASSAY INDUSTRY, BY REGION, 2021–2028 (USD MILLION)
     11.2 NORTH AMERICA 
                        FIGURE 38 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET SNAPSHOT
             TABLE 58 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 59 NORTH AMERICA: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             TABLE 60 NORTH AMERICA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 61 NORTH AMERICA: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
             TABLE 62 NORTH AMERICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 63 NORTH AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.2.1 IMPACT OF ECONOMIC RECESSION ON NORTH AMERICA
             11.2.2 US
                        11.2.2.1 US to hold largest share in North American chemiluminescence immunoassay market during forecast period
                                     TABLE 64 US: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                     TABLE 65 US: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                     TABLE 66 US: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
                                     TABLE 67 US: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                     TABLE 68 US: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.2.3 CANADA
                        11.2.3.1 Rising government initiatives and funding for early disease diagnosis to drive market
                                     TABLE 69 CANADA: ESTIMATED PREVALENCE OF DIABETES
                                     TABLE 70 CANADA: MACROECONOMIC INDICATORS
                                     TABLE 71 CANADA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                     TABLE 72 CANADA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                     TABLE 73 CANADA: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
                                     TABLE 74 CANADA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                     TABLE 75 CANADA: MARKET, BY END USER, 2021–2028 (USD MILLION)
     11.3 EUROPE 
             TABLE 76 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 77 EUROPE: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             TABLE 78 EUROPE: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 79 EUROPE: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
             TABLE 80 EUROPE: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 81 EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.1 IMPACT OF ECONOMIC RECESSION ON EUROPE
             11.3.2 GERMANY
                        11.3.2.1 Growing investments in clinical diagnostics research and increasing government spending on healthcare to drive market
                                     TABLE 82 GERMANY: MACROECONOMIC INDICATORS
                                     TABLE 83 GERMANY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                     TABLE 84 GERMANY: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                     TABLE 85 GERMANY: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
                                     TABLE 86 GERMANY: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                     TABLE 87 GERMANY: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.3 FRANCE
                        11.3.3.1 Favorable reimbursement policies and increased investments in diagnostics to drive market
                                     TABLE 88 FRANCE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                     TABLE 89 FRANCE: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                     TABLE 90 FRANCE: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
                                     TABLE 91 FRANCE: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                     TABLE 92 FRANCE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.4 UK
                        11.3.4.1 Increasing number of accredited clinical laboratories and growing accessibility to IVD tests to drive market
                                     TABLE 93 UK: MACROECONOMIC INDICATORS
                                     TABLE 94 UK: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                     TABLE 95 UK: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                     TABLE 96 UK: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
                                     TABLE 97 UK: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                     TABLE 98 UK: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.5 ITALY
                        11.3.5.1 Growing geriatric population and increasing support for research to drive market
                                     TABLE 99 ITALY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                     TABLE 100 ITALY: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                     TABLE 101 ITALY: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
                                     TABLE 102 ITALY: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                     TABLE 103 ITALY: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.6 SPAIN
                        11.3.6.1 Rising adoption of technologically advanced immunoassay systems to drive market
                                     TABLE 104 SPAIN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                     TABLE 105 SPAIN: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                     TABLE 106 SPAIN: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
                                     TABLE 107 SPAIN: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                     TABLE 108 SPAIN: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.7 REST OF EUROPE
                        TABLE 109 REST OF EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 110 REST OF EUROPE: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 111 REST OF EUROPE: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
                        TABLE 112 REST OF EUROPE: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 113 REST OF EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
     11.4 ASIA PACIFIC 
                        FIGURE 39 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET SNAPSHOT
             TABLE 114 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 115 ASIA PACIFIC: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             TABLE 116 ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 117 ASIA PACIFIC: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
             TABLE 118 ASIA PACIFIC: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 119 ASIA PACIFIC: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.1 IMPACT OF ECONOMIC RECESSION ON ASIA PACIFIC
             11.4.2 JAPAN
                        11.4.2.1 Growing investments in clinical diagnostics research to drive market
                                     TABLE 120 JAPAN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                     TABLE 121 JAPAN: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                     TABLE 122 JAPAN: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
                                     TABLE 123 JAPAN: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                     TABLE 124 JAPAN: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.3 CHINA
                        11.4.3.1 China to register highest growth rate in Asia Pacific chemiluminescence immunoassay market during study period
                                     TABLE 125 CHINA: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                     TABLE 126 CHINA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                     TABLE 127 CHINA: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
                                     TABLE 128 CHINA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                     TABLE 129 CHINA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.4 INDIA
                        11.4.4.1 Growing medical tourism and healthcare infrastructure to drive market
                                     TABLE 130 INDIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                     TABLE 131 INDIA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                     TABLE 132 INDIA: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
                                     TABLE 133 INDIA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                     TABLE 134 INDIA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.5 SOUTH KOREA
                        11.4.5.1 Rising healthcare spending for innovative IVD technologies to drive market
                                     TABLE 135 SOUTH KOREA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                     TABLE 136 SOUTH KOREA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                     TABLE 137 SOUTH KOREA: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
                                     TABLE 138 SOUTH KOREA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                     TABLE 139 SOUTH KOREA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.6 REST OF ASIA PACIFIC
                        TABLE 140 REST OF ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 141 REST OF ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 142 REST OF ASIA PACIFIC: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
                        TABLE 143 REST OF ASIA PACIFIC: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 144 REST OF ASIA PACIFIC: MARKET, BY END USER, 2021–2028 (USD MILLION)
     11.5 REST OF THE WORLD 
             TABLE 145 REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY REGION, 2021–2028 (USD MILLION)
             TABLE 146 REST OF THE WORLD: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             TABLE 147 REST OF THE WORLD: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 148 REST OF THE WORLD: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
             TABLE 149 REST OF THE WORLD: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 150 REST OF THE WORLD: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.5.1 IMPACT OF ECONOMIC RECESSION ON REST OF THE WORLD
             11.5.2 LATIN AMERICA
                        11.5.2.1 Rising incidence of infectious diseases and increasing geriatric population to drive market
                                     TABLE 151 LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                     TABLE 152 LATIN AMERICA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                     TABLE 153 LATIN AMERICA: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
                                     TABLE 154 LATIN AMERICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                     TABLE 155 LATIN AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.5.3 MIDDLE EAST & AFRICA
                        11.5.3.1 Lack of skilled laboratory personnel and unfavorable reimbursement policies to limit market
                                     TABLE 156 MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                     TABLE 157 MIDDLE EAST & AFRICA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                     TABLE 158 MIDDLE EAST & AFRICA: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
                                     TABLE 159 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                     TABLE 160 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
 
12 COMPETITIVE LANDSCAPE (Page No. - 221)
     12.1 OVERVIEW 
     12.2 STRATEGIES ADOPTED BY KEY PLAYERS 
             TABLE 161 OVERVIEW OF STRATEGIES ADOPTED BY KEY MANUFACTURERS OF CHEMILUMINESCENCE IMMUNOASSAY PRODUCTS
     12.3 REVENUE ANALYSIS OF TOP MARKET PLAYERS 
             FIGURE 40 REVENUE ANALYSIS OF TOP MARKET PLAYERS IN CHEMILUMINESCENCE IMMUNOASSAY MARKET
     12.4 MARKET SHARE ANALYSIS 
             TABLE 162 CHEMILUMINESCENCE IMMUNOASSAY INDUSTRY: DEGREE OF COMPETITION
             FIGURE 41 CHEMILUMINESCENCE IMMUNOASSAY INDUSTRY SHARE, BY KEY PLAYER (2022)
     12.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS 
             12.5.1 STARS
             12.5.2 EMERGING LEADERS
             12.5.3 PERVASIVE PLAYERS
             12.5.4 PARTICIPANTS
                        FIGURE 42 CHEMILUMINESCENCE IMMUNOASSAY INDUSTRY: COMPANY EVALUATION MATRIX FOR KEY PLAYERS
     12.6 COMPANY EVALUATION MATRIX FOR SMES/START-UPS 
             12.6.1 PROGRESSIVE COMPANIES
             12.6.2 STARTING BLOCKS
             12.6.3 RESPONSIVE COMPANIES
             12.6.4 DYNAMIC COMPANIES
                        FIGURE 43 CHEMILUMINESCENCE IMMUNOASSAY INDUSTRY: COMPANY EVALUATION MATRIX FOR START-UPS/SMES
     12.7 COMPETITIVE BENCHMARKING 
             TABLE 163 CHEMILUMINESCENCE IMMUNOASSAY INDUSTRY: DETAILED LIST OF KEY START-UPS/SMES
     12.8 COMPANY FOOTPRINT ANALYSIS 
             TABLE 164 OVERALL COMPANY FOOTPRINT
             TABLE 165 COMPANY PRODUCT FOOTPRINT
             TABLE 166 COMPANY REGIONAL FOOTPRINT
     12.9 COMPETITIVE SCENARIO 
             12.9.1 KEY PRODUCT LAUNCHES AND APPROVALS
                        TABLE 167 CHEMILUMINESCENCE IMMUNOASSAY INDUSTRY: KEY PRODUCT LAUNCHES AND APPROVALS, 2020–2023
             12.9.2 KEY DEALS
                        TABLE 168 CHEMILUMINESCENCE IMMUNOASSAY INDUSTRY: KEY DEALS, 2020–2023
             12.9.3 OTHER KEY DEVELOPMENTS
                        TABLE 169 CHEMILUMINESCENCE IMMUNOASSAY MARKET: OTHER KEY DEVELOPMENTS, 2020–2023
 
13 COMPANY PROFILES (Page No. - 236)
     13.1 KEY PLAYERS 
(Business Overview, Products/Solutions Offered, Recent Developments, SWOT Analysis, Winning Imperatives, Current Focus and Strategies, Threat From Competition, Right to Win)*
             13.1.1 F. HOFFMANN-LA ROCHE LTD.
                        TABLE 170 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
                        FIGURE 44 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
             13.1.2 DANAHER CORPORATION
                        TABLE 171 DANAHER CORPORATION: COMPANY OVERVIEW
                        FIGURE 45 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
             13.1.3 SIEMENS HEALTHINEERS AG
                        TABLE 172 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
                        FIGURE 46 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022)
             13.1.4 DIASORIN S.P.A.
                        TABLE 173 DIASORIN S.P.A.: COMPANY OVERVIEW
                        FIGURE 47 DIASORIN S.P.A.: COMPANY SNAPSHOT (2022)
             13.1.5 ABBOTT LABORATORIES
                        TABLE 174 ABBOTT LABORATORIES: COMPANY OVERVIEW
                        FIGURE 48 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022)
             13.1.6 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
                        TABLE 175 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY OVERVIEW
                        FIGURE 49 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY SNAPSHOT (2021)
             13.1.7 SYSMEX CORPORATION
                        TABLE 176 SYSMEX CORPORATION: COMPANY OVERVIEW
                        FIGURE 50 SYSMEX CORPORATION: COMPANY SNAPSHOT (2022)
             13.1.8 DIATRON
                        TABLE 177 DIATRON: COMPANY OVERVIEW
                        FIGURE 51 STRATEC SE: COMPANY SNAPSHOT (2022)
             13.1.9 GETEIN BIOTECH, INC.
                        TABLE 178 GETEIN BIOTECH, INC.: COMPANY OVERVIEW
             13.1.10 WERFEN
                        TABLE 179 WERFEN: COMPANY OVERVIEW
             13.1.11 QUIDELORTHO CORPORATION
                        TABLE 180 QUIDELORTHO CORPORATION: COMPANY OVERVIEW
                        FIGURE 52 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2022)
             13.1.12 EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG
                        TABLE 181 EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG: COMPANY OVERVIEW
*Business Overview, Products/Solutions Offered, Recent Developments, SWOT Analysis, Winning Imperatives, Current Focus and Strategies, Threat From Competition, Right to Win might not be captured in case of unlisted companies.
     13.2 OTHER PLAYERS 
             13.2.1 MERCK KGAA
             13.2.2 TOSOH CORPORATION (TOSOH BIOSCIENCE)
             13.2.3 TRIVITRON HEALTHCARE
             13.2.4 ABNOVA CORPORATION
             13.2.5 ELABSCIENCE
             13.2.6 MACCURA BIOTECHNOLOGY CO., LTD.
             13.2.7 AUTOBIO DIAGNOSTICS CO., LTD
             13.2.8 JIANGSU ZECEN BIOTECH CO., LTD
             13.2.9 RAYTO LIFE AND ANALYTICAL SCIENCES CO., LTD.
             13.2.10 DAAN GENE CO., LTD.
             13.2.11 DYNEX TECHNOLOGIES, INC.
             13.2.12 ZYBIO INC.
             13.2.13 WIENER LABORATORIOS SAIC
             13.2.14 TIANJIN ERA BIOLOGY TECHNOLOGY CO., LTD.
 
14 APPENDIX (Page No. - 275)
     14.1 DISCUSSION GUIDE 
     14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     14.3 CUSTOMIZATION OPTIONS 
     14.4 RELATED REPORTS 
     14.5 AUTHOR DETAILS 

The objective of the study is analyze the key market dynamics such as drivers, opportunities, challenges, restraints, and key player strategies. To track companies developments such as product launches and approvals, expansions, collaborations, agreements, and partnerships of the leading players, the competitive landscape of the chemiluminescence immunoassay market to analyzes market players on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches were use to estimate the market size. To estimate the market size of segments and subsegments the market breakdown and data triangulation were used.

The four steps involved in estimating the market size are

Collecting Secondary Data

The secondary research data collection process involves the usage of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B), annual reports, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the chemiluminescence immunoassay market. A database of the key industry leaders was also prepared using secondary research.

Collecting Primary Data

The primary research data was conducted after acquiring knowledge about the chemiluminescence immunoassay market scenario through secondary research. A significant number of primary interviews were conducted with stakeholders from both the demand side (such clinical laboratories, hospitals, and academic & research institutes) and supply-side (such as included various industry experts, such as Directors, Chief X Officers (CXOs), Vice Presidents (VPs) from business development, marketing and product development teams, product manufacturers, wholesalers, channel partners, and distributors) across major countries of North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America. Approximately 40% of the primary interviews were conducted with stakeholders from the demand side while those from the supply side accounted for the remaining 60%. Primary data for this report was collected through questionnaires, emails, and telephonic interviews.

A breakdown of the primary respondents is provided below:

Breakdown of Primary Participants

Chemiluminescence Immunoassay Market Size, and Share

Note 1: Others include sales managers, marketing managers, and product managers.

Note 2: Tiers are defined based on a company’s total revenue. As of 2022: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 <USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

COMPANY NAME

DESIGNATION

F. Hoffmann-La Roche Ltd. (Switzerland)

Regional Head of Sales

Danaher Corporation (US)

Senior Product Manager

Siemens Healthineers (Germany)

Regional Manager

Abbott Laboratories (US)

General Manager

Market Size Estimation

All major product manufacturers offering various chemiluminescence immunoassay were identified at the global/regional level. Revenue mapping was done for the major players and was extrapolated to arrive at the global market value of each type of segment. The market value chemiluminescence immunoassay market was also split into various segments and subsegments at the region and country level based on:

  • Product mapping of various manufacturers for each type of chemiluminescence immunoassay market at the regional and country-level
  • Relative adoption pattern of each chemiluminescence immunoassay market among key application segments at the regional and/or country-level
  • Detailed primary research to gather qualitative and quantitative information related to segments and subsegments at the regional and/or country level.
  • Detailed secondary research to gauge the prevailing market trends at the regional and/or country-level

Global Chemiluminescence Immunoassay Market Size: Botton Up Approach

Chemiluminescence Immunoassay Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Global Chemiluminescence Immunoassay Market Size: Top Down Approach

Chemiluminescence Immunoassay Market Size, and Share

Data Triangulation

After arriving at the overall market size—using the market size estimation processes—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the chemiluminescence immunoassay industry.

Market Definition

Chemiluminescent immunoassay (CLIA) is an immunoassay technique where the label, i.e., the indicator of the analytic reaction, is a luminescent molecule. CLIA is a variation of the standard enzyme immunoassay (EIA), a biochemical technique used in immunology. This variation technique can be used for diagnosis in medicine and in several other different industries for various applications. In recent years, CLIA has gained increasing attention in different fields, including clinical diagnosis, life science, food safety, environmental monitoring, and pharmaceutical analysis, due to its good specificity, high sensitivity, wide applications, simple equipment, and wide linear range.

Key Stakeholders

  • Senior Management
  • End User
  • Finance/Procurement Department
  • R&D Department

Report Objectives

  • To provide detailed information about the factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To define, describe, segment, and forecast the chemiluminescence immunoassay market by product, technology, sample type, application, end user, and region
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall chemiluminescence immunoassay market
  • To forecast the size of the chemiluminescence immunoassay market in four main regions along with their respective key countries, namely, North America, Europe, the Asia Pacific and Rest of the world
  • To profile key players in the chemiluminescence immunoassay market and comprehensively analyze their core competencies and market shares
  • To track and analyze competitive developments, such as product launches and approvals; expansions; collaborations, and agreements, & partnerships; of the leading players in the chemiluminescence immunoassay market
  • To benchmark players within the chemiluminescence immunoassay market using the Competitive Leadership Mapping framework, which analyzes market players on various parameters within the broad categories of business and product strategy

Available Customizations

MarketsandMarkets offers the following customizations for this market report

Country Information

  • Additional country-level analysis of the chemiluminescence immunoassay market

Company profiles

  • Additional three company profiles of players operating in the chemiluminescence immunoassay market.

Product Analysis

  • Product matrix, which provides a detailed comparison of the product portfolio of each company in the chemiluminescence immunoassay market
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization
Report Code
MD 8709
Published ON
Jul, 2023
REQUEST FREE SAMPLE REPORT
Choose License Type
BUY NOW
Inquire Before Buying
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Chemiluminescence Immunoassay Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback